Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million (CHF 420 million). Burgdorf, Switzerland–based Ypsomed says the sale helps it focus on strengthening its position in the subcutaneous self-injection market. TecMed — also based in Burgdorf — can now add Ypsomed’s insulin delivery technology […]
Wall Street Beat
Retractable Technologies cuts workforce as it reduces reliance on China amid trade war
Retractable Technologies (NYSE:RVP) announced today that it reduced its workforce by approximately 7%. The Little Elm, Texas-based maker of products like syringes and needles said the move comes as it allocates more resources to the U.S. It aims to increase U.S. manufacturing capabilities and reduce reliance on products produced in China. According to a news […]
How ICU Medical plans to mitigate tariff impact
Needham analysts report that ICU Medical (Nasdaq: ICUI) has a plan in place to handle its exposure to the tariffs imposed by the Trump Administration. Medtech stocks already took a hit last month as in response to Trump’s tariff policies. Trump’s rollout of new taxes on imports from nearly all countries last week triggered the latest market dip. […]
Beta Bionics posts Q4 sales beat to cap off ‘momentum-building year’
Beta Bionics (Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of BBNX ticked up nearly 2% to $15.50 apiece in poost-market trading today. This is the company’s first quarterly earnings report after it went public through a $234.6 million IPO in January. The Irvine, California-based automated insulin […]
Vivani to spin out neurostim business, focus on GLP-1 implant
Vivani Medical (Nasdaq:VANI) announced today that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic areas. Vivani aims to continue advancing its miniature GLP-1 therapeutic implants. The spin-off would enable Cortigent to continue […]
Senseonics expects to double global patient base in 2025, progresses with pump integration
Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of SENS went up nearly 7% to 93¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $15.5 million for the quarter. That equals losses 2¢ per […]
Pump shipments increase by 25% in Q4 sales beat for Tandem
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours today on fourth-quarter results that topped the consensus sales forecast. Shares of TNDM fell 11% to $29.88 apiece in post-market trading today. The San Diego-based automated insulin delivery technology company reported profits of $755,000. That equals 1¢ per share on sales of $282.65 million for […]
Insulet sales increase 22% in 2024, Q4 performance beats Street
Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of PODD fell 2.7% to $280.66 apiece in post-market trading on Thursday, Feb. 21. By midday trading on Friday, Feb. 22, shares were down 2.4%, at 281.36. The Acton, Massachusetts–based automated insulin delivery technology maker reported […]
Medtronic seeks to expand MiniMed 780G label to type 2 diabetes, submits new CGM to FDA
Third-quarter results for Medtronic (NYSE:MDT) today included a timeline for a planned label expansion for its automated insulin delivery platform. The medtech giant posted an overall revenue miss for the three months, despite growth in the Diabetes business. (Read more about the company’s third-quarter results at sibling site MassDevice.) Speaking on the company’s earnings call […]
Dexcom posts Q4 EPS miss, analysts remain high on coming catalysts
Dexcom (Nadsaq:DXCM) announced fourth-quarter results that came in mixed compared to the consensus forecast — but analysts are optimistic about 2025. Shares of DXCM initially fell after-hours yesterday on the after-market-close report — but by midday today, they were up more than 5% to $89.03 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported […]
